Ras Al Khaimah, United Arab Emirates -Sunday, March 12th 2017 [ ME NewsWire ]
Julphar Gulf Pharmaceutical Industries conducted a periodic refresher training on “Current Good Manufacturing Practices (cGMP) and safety at workplace” for 500 employees working in the areas of packaging,during the month of February, 2017.
The training sessions were conducted by DrRubinaRafiqEjaz, Julphar’s Senior Manager in Training & Development,and provided the Julphar staff with real-world examples of GMP compliance. All courses are based on the US Food and Drug Administration (FDA) Title 21 of the Code of Federal Regulations (CFR) part 210/211, EU, the World Health Organization (WHO) and Ministry of Health (MOH) UAE guidelines.
Commenting on the training, Julphar’s Executive Director,MsFatemaNayea, said: “At Julphar, we believe that it is our duty to recall and reinforce on a regular basis our people’s knowledge, and encourage them to continue to comply with GMP regulations. Such investment from the company has a positive impact on thequality of our products and will ensure healthcare professionals (HCPs) and patients are satisfied with our brand.”
The cGMP training is built upon the foundation of fundamental topics, such asthe history of the GMP regulations;the customers’ expectations;the prevention of contamination, mix-ups, and errors;the good practices to be followed during packaging operations; and the safety program to guarantee safety at work.
Established in 1980, Julphar is the largest generic pharmaceutical manufacturer in Middle East and North Africa, producing over 200 branded products across its fifteen manufacturing facilities. Julphar’smission is to offer high quality medicines at affordable prices, and its product portfolio includes: Wound Care & Biotechnology, Women Care, Adult Primary Care, Pediatric Primary Care, Gastro Care and Pain Management, Cardiopulmonary Care, and Consumer Care.In 2012 Julphar launched Julphar Diabetes, a 150 million-dollar Active Pharmaceutical Ingredient (API) manufacturing facility that has the capacity to produce 1,500 kg of recombinant human insulin and insulin analogues crystals (rDNA). Julphar employs approximately 3,000 people around the world and registered sales revenue of AED 1.47 billion in the year ending 2015.For more information, please visithttp://www.julphar.net.
Corporate Communication Manager
M +971-55-1934619, D +971-7-204-5209
Tel +971-7-246-1461, FAX +971-7-246-2462, firstname.lastname@example.org
Permalink : http://me-newswire.net/news/3532/en